Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to CSF-1R Inhibitor, EI-1071 for the Treatment of Idiopathic Pulmonary Fibrosis
Aug 2, 2022
Elixiron Immunotherapeutics, a clinical stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its colony stimulating factor‑1 receptor (CSF‑1R) inhibitor, EI‑1071 for the treatment of idiopathic pulmonary fibrosis (IPF).
"Idiopathic pulmonary fibrosis has a devastating impact on patients' lives and more effective therapies are urgently needed, and the Orphan Drug Designation validates the potential of EI‑1071 to offer a new therapeutic option for patients living with this disease," said Hung-Kai Kevin Chen, Chief Executive Officer of Elixiron. "Building on promising data from preclinical and phase I studies, we are actively evaluating options to accelerate the development of EI‑1071 to address unmet medical needs."
Orphan Drug Designation serves to support drug candidates in development for underserved patient populations or rare disorders that affect fewer than 200,000 people in the U.S., providing for various incentives including tax credits for eligible clinical trials, waiver of application fees, and market exclusivity for seven years upon FDA approval.
About Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic pulmonary fibrosis is a chronic interstitial lung disease characterized by tissue fibrosis and progressive decline in lung function. Currently, there is no cure for IPF and only two approved drugs slow but do not halt disease progression. On average, patients with IPF continue to live for only three to five more years once diagnosed with IPF.
About EI-1071
EI‑1071 is an orally-administered, small molecule inhibitor of colony stimulating factor‑1 receptor (CSF‑1R) that has completed Phase I development. CSF‑1 signaling plays an important role in the regulation of pulmonary macrophages which drive inflammatory damage and tissue fibrosis in IPF. CSF‑1R blockade with EI‑1071 shows promising therapeutic effects, ameliorating lung fibrosis and improving respiratory functions in preclinical models of IPF. Besides IPF, EI‑1071 can inhibit brain microglia-mediated neuroinflammation in preclinical models of Alzheimer's disease, and is being developed for treatment of Alzheimer's disease with funding support in part from the Alzheimer's Association Part the Cloud program.
About Elixiron Immunotherapeutics
Elixiron Immunotherapeutics is focused on the development of innovative immunotherapies to address unmet needs in rare and immunological diseases. Besides EI‑1071, Elixiron has an interferon-gamma-neutralizing antibody currently in a phase 1 trial that is being developed for the treatment of hemophagocytic lymphohistiocytosis and vitiligo. For more information, visit elixiron.com and follow the company on Linkedin.
Contact
Janie Chu
Email: [email protected]
Press Release Service by Newswire.com
Original Source: Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to CSF-1R Inhibitor, EI-1071 for the Treatment of Idiopathic Pulmonary Fibrosis
More News
G7 to release millions of barrels of oil and diesel after Trump threat
The co-ordinated release is aimed at heading off further price spikes and avoiding a ban on US diesel exports.
White House Filing Claims President Has Authority to Bar News Outlets
The Trump administration again defended the decision to bar CNN, MS NOW and Politico from the White House and to exclude journalists from the pool that covers the president in small spaces.
Federal Watchdog Investigates Adam Kinzinger for Kalshi Bets on His Pardon
The inquiry by the Commodity Futures Trading Commission centers on bets the former congressman made on Kalshi in the weeks before he was pardoned in January 2025.
US Sanctions A7, a Russia Firm That Helps Sidestep Economic Restrictions
The move followed reports detailing how A7, a Moscow firm, uses shell companies around the world to move funds for clients who are themselves subject to sanctions.
G20 trade ministers meet in Wisconsin amid trade tensions
G20 trade ministers meet in Wisconsin amid trade tensions
Chinese manufacturers dominate Latin America's bus fleet
Chinese manufacturers dominate Latin America's bus fleet
F.D.A. Found Cyclospora During Taylor Farms Inspection in Mexico
The discovery adds strong evidence that the outbreak that sickened thousands over the summer originated in a grower’s field or processing facility.
The Powerful Yet Fragile Force Propping Up Stocks and the Economy
The artificial intelligence boom has pushed up the stock market, even as interest rates have pulled it down, our columnist says.
Mash-Up of Paramount and Warner Bros. Will Be Called Skydance
David Ellison, the tech scion who will run the combined company, borrowed the name of his original entertainment company that reflects his love of aviation. On Friday, the C.E.O.s of Warner Bros. were told they would not stay on once the companies merged.
U.S. and Allies Agree to Release Diesel Reserves as Prices Soar
The Group of 7, which includes Britain, France and Japan, announced the release of 100 million barrels over four months, effective immediately.
Sales of Hulking Pickups and S.U.V.s Sag as Fuel Prices Soar
Sales of big pickup trucks and sport utility vehicles have dipped as more Americans buy hybrids and smaller cars.
Hiring Slows as U.S. Jobs Report Shows Labor Market Shifting Into Lower Gear
The economy added fewer jobs in September and unemployment ticked up, while inflation has maintained pressure on markets and raised costs.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.